Male Urinary Incontinence Market

The Global Male Urinary Incontinence Market is estimated to be valued at USD 6.82 Bn in 2025 and is expected to reach USD 10.19 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032. The global male urinary incontinence market represents a critical segment within the broader healthcare industry, addressing a prevalent yet often underreported condition affecting millions of men worldwide. Male urinary incontinence, characterized by the involuntary loss of bladder control, encompasses various types including stress incontinence, urge incontinence, overflow incontinence, and mixed incontinence, each presenting unique clinical challenges and treatment requirements. This condition predominantly affects older men, with prevalence rates increasing significantly with age, though it can also impact younger individuals due to factors such as prostate surgery, neurological disorders, or traumatic injuries.

The market encompasses a comprehensive range of therapeutic solutions including absorbent products, external catheters, implantable devices, pharmaceutical interventions, and surgical procedures designed to manage or treat the underlying causes of incontinence. Despite the significant impact on quality of life, social functioning, and psychological well-being, male urinary incontinence remains stigmatized, leading to underdiagnosis and delayed treatment seeking behavior among affected individuals, which consequently influences market dynamics and growth patterns across different geographical regions.

Market Dynamics

The global male urinary incontinence market is primarily driven by several interconnected factors that collectively propel market expansion and innovation within this therapeutic area. The aging global population serves as the most significant market driver, as the prevalence of urinary incontinence increases substantially with age, particularly among men over 65 years, creating a growing patient pool requiring management solutions. Rising awareness campaigns and educational initiatives by healthcare organizations and advocacy groups are gradually reducing the stigma associated with male incontinence, encouraging more men to seek professional medical help and appropriate treatment options. Technological advancements in medical devices, including the development of sophisticated artificial urinary sphincters, male slings, and minimally invasive surgical techniques, are expanding treatment possibilities and improving patient outcomes.

Additionally, the increasing prevalence of prostate-related disorders, including benign prostatic hyperplasia and prostate cancer requiring surgical intervention, directly contributes to the incidence of male urinary incontinence, thereby driving demand for both preventive and therapeutic solutions. However, market growth faces significant restraints including persistent social stigma and embarrassment associated with the condition, leading to underreporting and delayed diagnosis, which limits market penetration. High treatment costs, particularly for advanced surgical procedures and implantable devices, pose substantial barriers to access, especially in developing regions with limited healthcare infrastructure and insurance coverage. Regulatory complexities surrounding medical device approvals and pharmaceutical interventions can delay product launches and increase development costs for manufacturers. Nevertheless, substantial opportunities exist within emerging markets where improving healthcare infrastructure and increasing healthcare expenditure create new avenues for market expansion, while ongoing research into novel therapeutic approaches, including regenerative medicine and bioengineered solutions, promises to revolutionize treatment paradigms and capture untapped market potential.

Key Features of the Study

• This report provides an in-depth analysis of the global male urinary incontinence market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global male urinary incontinence market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Coloplast A/S, ConvaTec Group PLC, Hollister Incorporated, Kimberly-Clark Corporation, Medtronic PLC, Boston Scientific Corporation, B. Braun Melsungen AG, Teleflex Incorporated, Wellspect HealthCare, Procter and Gamble Co., AbbVie Inc., Pfizer Inc., Laboratoires URGO, Ontex Healthcare, and C. R. Bard (BD).
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global male urinary incontinence market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global male urinary incontinence market.

Market Segmentation

• Type of Incontinence Insights (Revenue, USD Bn, 2020 - 2032)
• Stress Urinary Incontinence
• Urge Urinary Incontinence
• Overflow Urinary Incontinence
• Functional Urinary Incontinence
• Mixed Incontinence (Stress + Urge)
• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
• Absorbent Products
• Pads and Guards
• Adult Diapers
• Protective Underwear
• Bed Protectors and Mattress Covers
• External Catheters (Urinary Sheaths)
• Latex Sheaths
• Silicone Sheaths
• Hydrocolloid Sheaths
• Internal Catheters
• Indwelling (Foley) Catheters
• Intermittent Catheters
• Other Devices and Systems
• Male Slings
• Artificial Urinary Sphincters
• Electrical Stimulation Devices/Penile Clamps
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
• 18–39 Years
• 40–59 Year
• 60–74 Years
• 75 Years and Above
• Usage Type Insights (Revenue, USD Bn, 2020 - 2032)
• Reusable
• Disposable
• End User Insights (Revenue, USD Bn, 2020 - 2032)
• Hospitals
• Urology Clinics
• Home Healthcare Settings
• Long-Term Care Centers / Nursing Homes
• Ambulatory Surgical Centers
• Others
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Offline
• Online
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Coloplast A/S
• ConvaTec Group PLC
• Hollister Incorporated
• Kimberly-Clark Corporation
• Medtronic PLC
• Boston Scientific Corporation
• Braun Melsungen AG
• Teleflex Incorporated
• Wellspect HealthCare
• Procter and Gamble Co.
• AbbVie Inc.
• Pfizer Inc.
• Laboratoires URGO
• Ontex Healthcare
• R. Bard (BD)

Show more